Foresee Pharmaceuticals announced the relocation of its R&D Centre to the National Biotechnology Research Park (NBRP) in January this year. The expanded establishment of Foresee's R&D Centre in the Park is expected to combine the ample R&D resources of the Park to inject innovative R&D energy into Taiwan's biotechnology industry.

According to the company, CAMCEVI, a long-acting injectable for the treatment of advanced prostate cancer, has been successfully marketed in the US and is being replicated in the adaptation of CAMCEVI for central precocious puberty in children and other applications; FP-025 (Aderamastat), a new ingredient, has been tested in the Phase II clinical proof-of-concept positive phase analysis for the treatment of allergic asthma, and in the previously published The positive results of the Phase II clinical proof-of-concept for the new ingredient FP-025 (Aderamastat) for the treatment of allergic asthma and the previously announced biomarker data results of the Phase II clinical trial of COVID-19 for acute respiratory distress syndrome (ARDS) in critically ill patients demonstrate the opportunity to expand investment in research and development.

On the 13th, executives from the US subsidiary were invited to join key members of the NBRP team for a tour of the core facilities and a visit to the newly opened R&D laboratories.

CAMCEVI 42 mg has been licensed in the US, Canada and Europe and is currently under review in Israel, Taiwan and the UK. CAMCEVI 21 mg is in preparation for US and European licensure, with US approval expected in 2024; CAMCEVI 42 mg is also being tested in a multi-centre Phase III clinical trial in children with central precocious puberty, a second indication.

In addition, the Phase II clinical proof-of-concept trial of FP-025 (Aderamastat), a highly selective MMP-12 (matrix metalloprotein-12) inhibitor and new ingredient for the treatment of chronic asthma in the Netherlands, has been completed and key analytical results are expected in March.